Gemcitabine-cisplatin chemotherapy plus anti-PD-L1 therapy reinvigorates antitumor immune response by reprogramming the intrahepatic cholangiocarcinoma microenvironment
Our preliminary findings reveal a generally reactivated antitumor immune response in ICC following GCP therapy, which could partly illuminate the enigmatic black box of intra-tumoral cellular states associated with treatment response.
Authors
- Bo Shu (ORCID: https://orcid.org/0000-0003-3443-8310)
- Yang Song (ORCID: https://orcid.org/0000-0001-7716-9216)
- Bao‐Ye Sun (ORCID: https://orcid.org/0000-0002-6802-5904)
- Weidong Dai (ORCID: https://orcid.org/0000-0002-9593-138X)
- Yingxia Zhou
- Shaowei Huang
Institutions
- Central South University (CN)
- Second Xiangya Hospital of Central South University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-02
- DOI
- https://doi.org/10.3389/fimmu.2025.1666393
- Citations
- 1
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- National Natural Science Foundation of China
- Universidade de Macau
- Natural Science Foundation of Hunan Province